Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Molecular oxygen (O2) is a vital diatomic molecule that acts as the primary electron acceptor in aerobic respiration and a critical determinant of the tumor microenvironment's metabolic landscape (Vaupel et al., 1989, PMID: 2673568). In solid tumors, inadequate and disorganized vascularization often leads to regions of chronic or acute hypoxia, where oxygen levels fall significantly below physiological norms (Semenza, 2003, PMID: 12928690). This hypoxic state is a major driver of therapeutic resistance, particularly in radiotherapy, where oxygen is required to "fix" radiation-induced DNA damage into permanent chemical changes, a process known as the oxygen fixation hypothesis (Gray et al., 1953, PMID: 13112371). Furthermore, oxygen serves as a necessary substrate for photodynamic therapy (PDT) to generate cytotoxic singlet oxygen (Dougherty et al., 1998, PMID: 9630877). Therapeutic interventions targeting intratumoral oxygen levels include the use of hyperbaric oxygen, oxygen-carrying perfluorocarbons, and diffusion enhancers like trans-sodium crocetinate to sensitize hypoxic cells to treatment (Gainer et al., 2005, PMID: 16144464). Conversely, the steep oxygen gradient in tumors is exploited by hypoxia-activated prodrugs, which remain non-toxic in well-oxygenated tissues but are converted to active cytotoxins in the O2-depleted tumor core (Wilson & Hay, 2011, PMID: 21455171).
Molecular oxygen acts as a radiosensitizer by reacting with radiation-induced DNA radicals to form stable, lethal peroxyl radicals, thereby preventing DNA repair (Oxygen Fixation Hypothesis; Gray et al., 1953, PMID: 13112371). It also serves as a critical substrate for photodynamic therapy, where it is converted into singlet oxygen and other reactive oxygen species (ROS) to induce cell death (Dougherty et al., 1998, PMID: 9630877). Additionally, oxygen levels modulate the activity of hypoxia-inducible factors (HIFs), which regulate genes involved in angiogenesis, metabolism, and cell survival (Semenza, 2003, PMID: 12928690).
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Molecular oxygen (O2) (O2).